GLP-1 receptor agonists at the crossroads of obesity and addiction: A review of shared neurobiology and translational evidence.
GLP-1 drugs target shared brain pathways between obesity and addiction, suggesting they might help reduce cravings beyond their proven weight-loss benefits.
This review explores the neurobiological intersection between obesity and addiction that GLP-1 receptor agonists modulate, synthesizing preclinical and clinical evidence for shared reward pathway mechanisms. The findings support investigation of GLP-1 RAs for addiction-related indications beyond their established metabolic indications.
What the study was
- Study design
- Review
- Population
- Patients with obesity and/or addiction disorders
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Pharmacology, Biochemistry and Behavior
Why it surfaced
Interesting GLP-1 neuro-behavioral review; emerging evidence for addiction applications is a secondary but growing area of relevance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.